T/FIF Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JFitnich who wrote (823)	4/20/1999 8:38:00 PM
From: Miljenko Zuanic	Read Replies (1) of 1073

Thanks JF. As Rick posted, NRGN selected in 98 their lead CRFr antagonist candidate for late stage pre-clinical development. However, I had detected several patents and patent applications on CRFr antagonist and their application (US, EU and worldwide). So, I was interested did any of this applicant actually pushed their programs/candidates forward. As Dr. Tracy stated, neuroscience show growing interest for this approach/target as depression/anxiety therapy, and it will be, imo, hot issue in near future. <<Maybe Dr. Tracy would care to shed some light.>> I hope to make peace with him, so I wish that he respond. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next